Overview
An experimental “fat-targeted” peptide that tries to kill the blood vessels feeding fat tissue, causing fat cells to die off.
It caused dramatic weight loss in monkeys, but also kidney damage.
Human safety is unproven.
This is the riskiest entry in this section.
What It Does
Adipotide (prohibitin-targeting peptide-1 / FTPP) is a proapoptotic peptide that homes to the vasculature of white adipose tissue and triggers programmed cell death of those vessels, starving fat tissue.
In primate studies it produced rapid fat loss but dose-dependent renal toxicity (proximal tubule injury).
No established human safety or dosing.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 2 mg | + 0.4 mL | 5 mg/mL |
| 5 mg | + 1 mL | 5 mg/mL |
| 10 mg | + 2 mL | 5 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F, best used within ~2–3 weeks (structure-based estimate); potency fades before the 28-day sterility limit, so keep it cold, dark, and use it sooner.
- Unknown in humans.
- Animal data showed rapid fat loss but with kidney injury, the risk/benefit is not established.
- Supply math Not applicable, no validated human dosing.
- Research compound only.
Safety & Patient Education
- Renal function (creatinine, eGFR, urinalysis) before, during, and after; mandatory if used at all Electrolytes and hydration status Out of range?
- Any creatinine rise or eGFR drop = kidney injury starting → stop immediately (this is the defining risk).
